NCT05066217View on ClinicalTrials.gov

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2029

Conditions
Lennox Gastaut Syndrome
Interventions
DRUG

Clemizole HCl

Clemizole HCl will be administered as an oral solution.

DRUG

Placebo

Placebo will be administered as an oral solution.

Trial Locations (4)

28211

RECRUITING

On-Site Clinical Solution, Raleigh

34746

RECRUITING

Rare Disease Research, Kissimmee

55113

RECRUITING

Minnesota Epilepsy Group, P.A., Roseville

07746

RECRUITING

Neurology Center for Epilepsy and Seizures, Marlboro

Sponsors

Lead Sponsor

Epygenix
All Listed Sponsors
collaborator

Harmony Biosciences Management, Inc.

INDUSTRY

lead

Epygenix

INDUSTRY